Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5244)
All Articles published online
|
Publishing Process of This Article
|
Sep 27, 2021 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142 [PMID: 34630880 DOI: 10.4254/wjh.v13.i9.1132] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i9/1132.htm |
| Number | Citing Articles |
| 1 |
Khi Yung Fong, Joseph Jonathan Zhao, Rehena Sultana, Joycelyn Jie Xin Lee, Suat Ying Lee, Stephen Lam Chan, Thomas Yau, David Wai Meng Tai, Raghav Sundar, Chow Wei Too. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2023; 12(1): 7 doi: 10.1159/000526639
|
| 2 |
Rajangad S. Gurtatta, Sydney E. Whalen, Charles E. Ray. Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents. Seminars in Interventional Radiology 2024; 41(01): 084 doi: 10.1055/s-0043-1778660
|
| 3 |
Feng Ren, Xiao Ding, Min Zheng, Mikhail Korzinkin, Xin Cai, Wei Zhu, Alexey Mantsyzov, Alex Aliper, Vladimir Aladinskiy, Zhongying Cao, Shanshan Kong, Xi Long, Bonnie Hei Man Liu, Yingtao Liu, Vladimir Naumov, Anastasia Shneyderman, Ivan V. Ozerov, Ju Wang, Frank W. Pun, Daniil A. Polykovskiy, Chong Sun, Michael Levitt, Alán Aspuru-Guzik, Alex Zhavoronkov. AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Chemical Science 2023; 14(6): 1443 doi: 10.1039/D2SC05709C
|
| 4 |
Vijith Vittal Shetty, Adithi Kellarai. Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Global Oncology 2022; (8) doi: 10.1200/GO.22.00118
|
| 5 |
Trinh Van Le, Nhung Hai Truong, Ai Xuan L. Holterman. Autophagy modulates physiologic and adaptive response in the liver. Liver Research 2023; 7(4): 304 doi: 10.1016/j.livres.2023.12.001
|
| 6 |
Suresh Bugide, Dhana Sekhar Reddy, Parmanand Malvi, Romi Gupta, Narendra Wajapeyee. ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience 2024; 27(5): 109800 doi: 10.1016/j.isci.2024.109800
|
| 7 |
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki. Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?. Livers 2022; 2(4): 315 doi: 10.3390/livers2040024
|
| 8 |
Po-Shuan Huang, Ling-Yu Wang, Yi-Wen Wang, Ming-Ming Tsai, Tzu-Kang Lin, Chia-Jung Liao, Chau-Ting Yeh, Kwang-Huei Lin. Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer. Cells 2023; 12(6): 869 doi: 10.3390/cells12060869
|
| 9 |
Edgar Xchel Franco-Juárez, Vianey González-Villasana, María Elena Camacho-Moll, Luisa Rendón-Garlant, Patricia Nefertari Ramírez-Flores, Beatriz Silva-Ramírez, Katia Peñuelas-Urquides, Ethel Daniela Cabello-Ruiz, Fabiola Castorena-Torres, Mario Bermúdez de León. Mechanistic Insights about Sorafenib-, Valproic Acid- and Metformin-Induced Cell Death in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2024; 25(3): 1760 doi: 10.3390/ijms25031760
|